Exchange Traded Concepts LLC Grows Position in Medtronic PLC $MDT

Exchange Traded Concepts LLC boosted its position in Medtronic PLC (NYSE:MDT) by 29.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 124,000 shares of the medical technology company’s stock after purchasing an additional 28,569 shares during the period. Exchange Traded Concepts LLC’s holdings in Medtronic were worth $11,911,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of MDT. Wealthcare Advisory Partners LLC grew its stake in shares of Medtronic by 6.0% during the fourth quarter. Wealthcare Advisory Partners LLC now owns 10,451 shares of the medical technology company’s stock valued at $1,004,000 after buying an additional 590 shares during the last quarter. Chemung Canal Trust Co. boosted its holdings in Medtronic by 1.3% during the 4th quarter. Chemung Canal Trust Co. now owns 67,218 shares of the medical technology company’s stock valued at $6,457,000 after acquiring an additional 845 shares during the period. Petros Family Wealth LLC boosted its holdings in Medtronic by 47.7% during the 4th quarter. Petros Family Wealth LLC now owns 3,239 shares of the medical technology company’s stock valued at $311,000 after acquiring an additional 1,046 shares during the period. Wolff Wiese Magana LLC grew its position in Medtronic by 0.9% in the 4th quarter. Wolff Wiese Magana LLC now owns 20,651 shares of the medical technology company’s stock valued at $1,984,000 after acquiring an additional 188 shares during the last quarter. Finally, Leonard Rickey Investment Advisors P.L.L.C. increased its stake in Medtronic by 2.3% in the fourth quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 5,140 shares of the medical technology company’s stock worth $494,000 after purchasing an additional 118 shares during the period. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on MDT. Needham & Company LLC reissued a “buy” rating and set a $120.00 target price on shares of Medtronic in a research note on Thursday. JPMorgan Chase & Co. reduced their price target on shares of Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 18th. Barclays reiterated an “overweight” rating and set a $118.00 price objective on shares of Medtronic in a report on Wednesday, February 18th. CICC Research began coverage on shares of Medtronic in a research note on Friday, January 30th. They issued an “outperform” rating on the stock. Finally, Citigroup assumed coverage on shares of Medtronic in a research report on Tuesday, February 3rd. They set a “buy” rating and a $117.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, Medtronic has a consensus rating of “Moderate Buy” and an average price target of $110.74.

Medtronic Stock Performance

MDT stock opened at $87.20 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. The business has a 50-day moving average price of $95.80 and a 200 day moving average price of $96.49. The company has a market capitalization of $111.96 billion, a P/E ratio of 24.29, a PEG ratio of 2.24 and a beta of 0.71. Medtronic PLC has a 1-year low of $79.55 and a 1-year high of $106.33.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.02. The company had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the business earned $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities research analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be paid a dividend of $0.71 per share. The ex-dividend date is Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.3%. Medtronic’s dividend payout ratio (DPR) is currently 79.11%.

Insider Transactions at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 0.26% of the stock is currently owned by insiders.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: FDA clearance expands addressable market for Stealth AXiS — The U.S. FDA cleared Medtronic’s Stealth AXiS surgical system for cranial and ENT procedures, adding to the spine clearance received in February. The broader indication increases the platform’s market opportunity for navigation + robotics in higher‑value neurosurgical/ENT cases, supporting future procedure volume and device sales. Medtronic gets US FDA nod to use surgical system in cranial, ENT surgeries
• Positive Sentiment: Distribution deal adds a minimally invasive pain product to the portfolio — Medtronic expanded distribution with Merit Medical for the ViaVerte™ basivertebral nerve ablation (BVNA) system, a minimally invasive, implant‑free therapy for chronic low back pain. This is a commercially relevant, non‑capital product that could contribute recurring revenue and broaden Medtronic’s spine/pain offerings. Medtronic (MDT) Expands Partnership with Merit Medical for ViaVerte System
• Positive Sentiment: Analyst reaffirmation with a high price target — Needham reiterated a Buy rating and $120 price target on MDT, signaling continued analyst confidence in Medtronic’s multi‑year growth thesis (including tuck‑ins, robotics, and margin improvement). That target implies substantial upside from current levels and can support investor sentiment. Needham Reiterates Buy Rating on Medtronic
• Positive Sentiment: Strategic spin‑off plan remains a potential value catalyst — Coverage highlights Medtronic’s planned spin‑off of its high‑growth diabetes unit later this year. A diabetes spin‑off could unlock value for the parent (focused on cardiovascular, robotics, and other higher‑margin hospital businesses) and make both entities more strategically coherent. 5 Spin-Off Stocks That Could Reward Patient Investors in 2026
• Neutral Sentiment: Investor writeups argue the company is set for faster growth — Recent commentary (e.g., Seeking Alpha’s “Time For A Growth Spurt”) lays out a bullish case around robotics, procedure growth, and margin leverage; these are thematic/analytical pieces rather than direct catalysts. Impact timing is uncertain. Medtronic: Time For A Growth Spurt
• Negative Sentiment: Near‑term technicals and volume suggest selling pressure — MDT is trading below its 50‑ and 200‑day moving averages with intraday volume above average, a setup that can keep the stock under pressure despite positive fundamental news until technicals stabilize.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).